These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 1724347

  • 1. [PSA in the staging and monitoring of cancer of the prostate].
    Gil Sanz MJ, Sanz Velez JI, Liedana Torres JM, Roncales Badal AL, Allepuz Losa C, Rioja Sanz LA.
    Actas Urol Esp; 1991; 15(6):527-31. PubMed ID: 1724347
    [Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E.
    N Engl J Med; 1987 Oct 08; 317(15):909-16. PubMed ID: 2442609
    [Abstract] [Full Text] [Related]

  • 3. [Prostatic specific antigen for detection and monitoring of prostatic cancer].
    Gofrit O, Pode D, Gez E, Pfau A, Roizman I, Lifshitz Y, Barak V.
    Harefuah; 1992 Mar 15; 122(6):345-8, 408. PubMed ID: 1374729
    [Abstract] [Full Text] [Related]

  • 4. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M, Kovacić K, Kastelan M.
    Anticancer Res; 1993 Mar 15; 13(1):215-8. PubMed ID: 7682800
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 15; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 7. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M.
    Anticancer Res; 1988 Feb 15; 8(4):569-72. PubMed ID: 2460018
    [Abstract] [Full Text] [Related]

  • 8. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M.
    Anticancer Res; 1993 Feb 15; 13(3):769-77. PubMed ID: 7686362
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
    Kabalin JN.
    Geriatrics; 1992 Sep 15; 47(9):26-32. PubMed ID: 1380941
    [Abstract] [Full Text] [Related]

  • 11. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S, Akakura K, Shimazaki J.
    Hinyokika Kiyo; 1988 Aug 15; 34(8):1389-96. PubMed ID: 2461644
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA, Ekman PE, Blankenstein MA, Cooper EH, Kontturi M, Lilja H, Oesterling JE, Stenman UH, Turkes A.
    Scand J Urol Nephrol Suppl; 1994 Aug 15; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [Abstract] [Full Text] [Related]

  • 14. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
    Gomella LG, Raj GV, Moreno JG.
    J Urol; 1997 Aug 15; 158(2):326-37. PubMed ID: 9224297
    [Abstract] [Full Text] [Related]

  • 15. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
    Schmid HP.
    Cancer Surv; 1995 Aug 15; 23():157-67. PubMed ID: 7542562
    [Abstract] [Full Text] [Related]

  • 16. Tumour serum markers: clinical and economical aspects.
    Kardamakis D.
    Anticancer Res; 1996 Aug 15; 16(4B):2285-8. PubMed ID: 8694557
    [Abstract] [Full Text] [Related]

  • 17. [Prostate-specific antigen as a prostatic tumor marker. Analysis of results in 206 patients].
    Rodríguez Duarte C.
    Arch Esp Urol; 1991 Aug 15; 44(6):697-700. PubMed ID: 1722962
    [Abstract] [Full Text] [Related]

  • 18. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A, Simşek F, Ilker Y, Türkeri L, Ercan H.
    Int Urol Nephrol; 1993 Aug 15; 25(3):271-8. PubMed ID: 7693607
    [Abstract] [Full Text] [Related]

  • 19. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff JM, Seiter H, Schuff-Werner P.
    Anticancer Res; 2000 Aug 15; 20(6D):4995-6. PubMed ID: 11326656
    [Abstract] [Full Text] [Related]

  • 20. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.
    Clin Cancer Res; 2005 Sep 15; 11(18):6582-8. PubMed ID: 16166436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.